The prespecified interim analysis of the RENOTORCH study showed toripalimab plus axitinib improved progression-free survival, overall response rates, and showed no new safety signals among patients with renal cell carcinoma.
The primary end point of progression free survival (PFS) has met the pre-defined efficacy boundary, according to the prespecified interim analysis of the RENOTORCH study (NCT04394975) evaluating toripalimab (Tuoyi) in combination with axitinib (Inlyta) for the first-line treatment of patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma (RCC).1
In the interim analysis of the RENOTORCH study, the combination of toripalimab with axitinib for the first-line treatment of patients with advanced RCC significantly reduced the risk of disease progression or death vs sunitinib monotherapy. The combination also led to improvements in the secondary end points, including overall response rate (ORR). Regarding safety, the safety profile of toripalimab determined in the trial was consistent with known risks. Additionally, no new safety signals were identified.
With the phase 3 trial completed, Junshi Biosciences will discuss matters related to the supplemental new drug application with regulatory authorities in the near future.
“Thanks to the collective efforts of the investigators, patients, [research and development] teams and many others, the RENOTORCH study has been a great success,” said Jianjun Zou, global research and development president of Junshi Biosciences, in the press release. “This study represents a crucial milestone for our company as an innovative Chinese pharmaceutical company that aims to address the nation’s unmet medical needs.”
RENOTORCH is a multi-center, randomized, open-label, active-controlled, phase 3 clinical study evaluating the efficacy and safety of the combination of toripalimab and axitinib vs sunitinib monotherapy for the first-line treatment of patients with intermediate to high-risk unresectable or metastatic RCC.2 It is the first pivotal phase 3 study of immunotherapy for patients with advanced RCC in China.
Enrolled individuals were randomly assigned in a 1:1 ratio to receive toripalimab in combination with either axitinib or sunitinib until disease progression or intolerable toxicity.
In the experimental arm, patients received toripalimab 240 mg intravenously every 3 weeks plus axitinib 5 mg orally twice daily. In the control arm, patients were given sunitinib 50 mg orally once daily for 4 weeks followed by off treatment for 2 weeks, or once daily for 2 weeks, followed by 1 week off treatment.
The primary endpoint is PFS, and secondary end points of the study include PFS as assessed by investigators, ORR, duration of response (DOR), disease control rate (DCR), overall survival, and safety.
Further details on the study data will be presented at an upcoming international academic conference.1
“We believe that RENOTORCH’s positive results will help bridge the gap in renal cancer PD-[L]1 immunotherapy in China, and we will take all the necessary steps to commercialize this achievement and provide new and effective combination immunotherapy options for domestic patients,” added Zou.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More